| 查看: 2508 | 回复: 11 | ||||
| 当前只显示满足指定条件的回帖,点击这里查看本话题的所有回帖 | ||||
lixia2010木虫 (著名写手)
|
[交流]
拒稿,这样子重投么?已有9人参与
|
|||
|
Your manuscript has been reviewed by expert referees, and their critiques are attached below. I regret to have to inform you that, in its present form, it is not considered suitable for publication in Biol. Pharm. Bull. Your manuscript has therefore been rejected. Although, of course, we could give no guarantee of ultimate acceptance at this stage, we would not rule out the possibility of your submitting an entirely new paper with a new number and date of receipt, based on this work, providing you are able to deal with all of the criticisms raised by the reviewers. If you decide to submit a new manuscript in time, please be sure to attach a separate document (supplemental file) that carefully addresses, point-by-point, the issues raised in the reviewer∏s comments. Comments by Reviewer #1: The manuscript entitled ∪A novel **, induces apoptosis in MCF-7 cells involving ROS generation and mitochondria activation∩ describes anti-cancer effects and its possible mechanisms of OEL. Most of the study is well designed, however, there are some problems with interpretation of the data presented. Major comments: 1) Experimental section should be revised carefully. In particular, no detailed procedures were shown in ∪MTT assay∩. 2) Page 5/Cytotoxicity of OEL in cancer cell lines: Authors claimed ∪OEL had a lower cytotoxicity on normal cells∩, and reviewer agree partly. However, in my opinion, OEL can NOT be safe anti-cancer drug because of limited selectivity. This should be addressed in Discussion section. 3) No efforts have been made to clarify the possible target biomolecules (enzymes, receptors, or other proteins) for OEL, although authors presented a few possible mechanism. 4) Authors should specify the type of ROS in more detail. 5) It is still unclear why authors made a choice of these tumor and normal cells. Authors should show rationale(s) for selection. 6) Fig.3: Apoptotic death seemed to be induced without OEL stimulation. Authors should show the possible reasons. If it can be natural apoptosis in the cultured cells, the data in Fig. 3 is not in agreement with Fig. 2 partly, since viability of cells without OEL stimulation was found to be 100% even after 72-h treatment. Comments by Reviewer #2: The manuscript by Li et al. is a study of a novel compound (OEL) isolated from Chinese herb inducing apotosis in MCF-7 cells involving ROS generation and mitochondria activation. In whole, there are of some interest in the current data obtained herein, but these in vitro data seem to be preliminary. In fact, to demonstrate the anti-cancer effect of this compound, the in vivo study should be performed. Thus, the current study has some limitation for the conclusion. If possible, the authors should provide some in vivo data for anti-cancer effect, and the current in vitro data may give the basis for the in vivo data. 请求帮助,投稿1.8左右的,给了这样的回复 |
» 收录本帖的淘帖专辑推荐
★论文写作与投稿经验精华☆ |
» 猜你喜欢
Bioresource Technology期刊,第一次返修的时候被退回好几次了
已经有7人回复
2025冷门绝学什么时候出结果
已经有4人回复
真诚求助:手里的省社科项目结项要求主持人一篇中文核心,有什么渠道能发核心吗
已经有8人回复
寻求一种能扛住强氧化性腐蚀性的容器密封件
已经有5人回复
论文投稿,期刊推荐
已经有6人回复
请问哪里可以有青B申请的本子可以借鉴一下。
已经有4人回复
孩子确诊有中度注意力缺陷
已经有14人回复
请问下大家为什么这个铃木偶联几乎不反应呢
已经有5人回复
请问有评职称,把科研教学业绩算分排序的高校吗
已经有5人回复
天津工业大学郑柳春团队欢迎化学化工、高分子化学或有机合成方向的博士生和硕士生加入
已经有4人回复
» 本主题相关价值贴推荐,对您同样有帮助:
传闻像复旦这样的学校很多学生都不重视csc的
已经有46人回复
sci 被拒后,大修改后重投这个杂志有戏吗?
已经有35人回复
---------CrossCheck被拒后--------这样可以重投回去吗???
已经有8人回复
老板让审稿,刚才拒了一篇咱们中国人写的文章,心里有点难受!
已经有69人回复
拒稿后,是重投还是改投?
已经有37人回复
因为语言等细节问题被拒稿,修改后重投给原来的杂志收的可能性大么?
已经有9人回复
投了一个IF0.3的杂志,这样的审稿意见,还有希望重投别的杂志不?
已经有15人回复
编辑拒稿让重投,怎么办
已经有7人回复

liuying_hero
荣誉版主 (文学泰斗)
互助小英哥
- 应助: 1 (幼儿园)
- 贵宾: 1.749
- 金币: 16741.4
- 散金: 27311
- 红花: 47
- 沙发: 593
- 帖子: 89341
- 在线: 1730.4小时
- 虫号: 1042013
- 注册: 2010-06-15
- 性别: GG
- 专业: 细胞信号转导
- 管辖: 电脑疑难求助

11楼2010-11-07 16:23:20













回复此楼
